全文获取类型
收费全文 | 1477715篇 |
免费 | 105804篇 |
国内免费 | 8181篇 |
专业分类
耳鼻咽喉 | 18220篇 |
儿科学 | 46083篇 |
妇产科学 | 39175篇 |
基础医学 | 212543篇 |
口腔科学 | 37849篇 |
临床医学 | 138870篇 |
内科学 | 284942篇 |
皮肤病学 | 29231篇 |
神经病学 | 116720篇 |
特种医学 | 54899篇 |
外国民族医学 | 305篇 |
外科学 | 207178篇 |
综合类 | 45789篇 |
现状与发展 | 23篇 |
一般理论 | 585篇 |
预防医学 | 121889篇 |
眼科学 | 32326篇 |
药学 | 110204篇 |
121篇 | |
中国医学 | 8544篇 |
肿瘤学 | 86204篇 |
出版年
2021年 | 14742篇 |
2019年 | 13566篇 |
2018年 | 27436篇 |
2017年 | 22261篇 |
2016年 | 24642篇 |
2015年 | 18514篇 |
2014年 | 24838篇 |
2013年 | 34497篇 |
2012年 | 50239篇 |
2011年 | 59682篇 |
2010年 | 37611篇 |
2009年 | 33708篇 |
2008年 | 54859篇 |
2007年 | 59591篇 |
2006年 | 47281篇 |
2005年 | 47461篇 |
2004年 | 44591篇 |
2003年 | 43881篇 |
2002年 | 40806篇 |
2001年 | 59167篇 |
2000年 | 60171篇 |
1999年 | 50782篇 |
1998年 | 14845篇 |
1997年 | 13644篇 |
1996年 | 13712篇 |
1995年 | 12981篇 |
1994年 | 12127篇 |
1992年 | 39117篇 |
1991年 | 38512篇 |
1990年 | 37177篇 |
1989年 | 35892篇 |
1988年 | 33256篇 |
1987年 | 32528篇 |
1986年 | 30940篇 |
1985年 | 29142篇 |
1984年 | 22179篇 |
1983年 | 19400篇 |
1982年 | 11532篇 |
1979年 | 21153篇 |
1978年 | 15554篇 |
1977年 | 12879篇 |
1976年 | 11969篇 |
1975年 | 12852篇 |
1974年 | 15692篇 |
1973年 | 15429篇 |
1972年 | 14589篇 |
1971年 | 13596篇 |
1970年 | 12848篇 |
1969年 | 12130篇 |
1968年 | 11277篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
21.
As millions of people turn to social media for health information, better understanding the factors that guide health-related judgments and perceptions in this context is imperative. We report on two Web experiments (n > 400 total) examining the power of society’s widespread weight bias and related stereotypes to influence nutrition judgments in social media spaces. In Experiment 1, meals were judged as lower in nutritional quality when the person who recommended them (the source) was depicted as obese rather than of normal weight, an effect mediated by stereotypic beliefs about the source as a generally unhealthy person. Experiment 2 replicated this effect, which—notably—remained significant when controlling for objective nutritional information (calories and fat content). Results highlight spillover effects of weight bias that extend beyond person perception to color impressions of objects (here, food) that are associated with stigmatized attributes. Implications for everyday nutrition judgments and public health are considered. 相似文献
22.
23.
24.
25.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
26.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
27.
Sundaram Kavin Piuzzi Nicolas S. Patterson Brendan M. Stearns Kim L. Krebs Viktor E. Mont Michael A. 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):447-453
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate... 相似文献
28.
29.
文题释义:股骨头坏死中日友好医院分型的有限元分析:根据李子荣等提出的中日友好医院分型,建立股骨头坏死三维模型,分为 M型(内侧型)、C型(中央型)和 L型(外侧型),其中 L型包括L1型(次外侧型)、L2型(极外侧型)和 L3型(全头型)。通过对建立的模型进行有限元分析,为该分型的保髋治疗提供了一定力学依据,显示外侧柱的存留是精准预防塌陷的重要因素,为进一步实现个体化治疗提供力学基础。
腓骨支撑坏死股骨头保髋手术:是对于早中期股骨头坏死需要保留股骨头患者进行的一种手术方式。首先需对股骨头进行髓芯减压,清除一定坏死骨,空腔填塞松质骨(髂骨为主),打压结实后植入腓骨(异体或自体)支撑,给坏死区的提供力学支撑及生物学修复,预防股骨头进一步坏死及塌陷。
背景:研究报道股骨头坏死的保髋疗效与外侧柱存留密切相关,中日友好医院分型是根据三柱结构确立的,对股骨头塌陷的预测准确性高。
目的:建立股骨头坏死中日友好医院分型各分型仿真的三维有限元模型,通过有限元分析各分型腓骨植入的力学变化,探讨外侧柱存留对保髋疗效的意义,为该分型的塌陷精准预测提供基础。
方法:建立正常股骨头、中日友好医院分型(M型、C型、L1型、L2型、L3型)股骨头坏死及其腓骨植入3组11种三维有限元模型,运用ANSYS软件进行有限元分析计算,观察各组模型的最大应力值、最大位移值及股骨头内部载荷传递模式。
结果与结论:①坏死组位移最大,应变最大,且因坏死分型不同而位移不同,位移变化如下:M型相似文献
30.